Anti‐tumor drug supervision in China from 2010 to 2024: the evolution and prospect of drug review standards - Ling Tang; Yuanyuan Song; Hong Zhang; Ruimin Hao; Xin Tong; Xing Ai; Jun Ma; Zhimin Yang (Cancer Communications)